naa a22 4500 510763278 CHVBK 20180411083147.0 cr unu---uuuuu 180411e20130601xx s 000 0 eng 10.1007/s12094-012-0956-2 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0956-2 Stereotactic ablative radiotherapy delivered by image-guided helical tomotherapy for extracranial oligometastases [Elektronische Daten] [C. Sole, J. Lopez Guerra, R. Matute, J. Jaen, F. Puebla, E. Rivin, A. Sanchez-Reyes, C. Beltran, C. Bourgier, F. Calvo, H. Marsiglia] Purpose: To investigate the outcomes and risk factors of patients treated with stereotactic ablative radiotherapy (SABR) delivered by image-guided helical tomotherapy (HT) for extracranial oligometastases. Methods: From August 2006 through July 2011, 42 consecutive patients (median age 69years [range 16-87]) with oligometastases (≤3) received HT to all known cancer sites (lung, n=28; liver, n=12; adrenal, n=2). Prognostic factors were assessed by Cox's proportional hazards regression analysis. Results: A total of 60 lesions were treated with hypofractionated HT (median dose 39Gy [range 36-72.5]; median dose per fraction 12Gy [range 5-20]). Complete or partial response was observed in 40 (54%) patients. With a median follow-up period of 15months, 1- and 2-year overall survival (OS) was 84 and 63%, respectively; and 1- and 2-year local control (LC) was 92 and 86%, respectively. Four patients had pneumonitis Grade ≥2 and two patients had lower gastrointestinal toxicity Grade ≥2. Only the lack of complete/partial response was associated with higher risk of mortality on univariate (HR=3.8, P=0.04) and multivariate (HR=6.6, P=0.01) analyses. Conclusions: SABR delivered by image-guided HT is well tolerated and offers adequate LC with low acute morbidity in patients with extracranial oligometastatic disease. We found that the response to HT was the only predictor for OS. Federación de Sociedades Españolas de Oncología (FESEO), 2012 SABR nationallicence Helical tomotherapy nationallicence Oligometastases nationallicence Outcome nationallicence Sole C. Department of Radiation Oncology, Instituto Madrileño de Oncología/Grupo IMO, 28010, Madrid, Spain aut Lopez Guerra J. Department of Radiation Oncology, Instituto Madrileño de Oncología/Grupo IMO, 28010, Madrid, Spain aut Matute R. Department of Radiation Oncology, Instituto Madrileño de Oncología/Grupo IMO, 28010, Madrid, Spain aut Jaen J. Department of Radiation Oncology, Instituto Madrileño de Oncología/Grupo IMO, 28010, Madrid, Spain aut Puebla F. Department of Radiation Oncology, Instituto Madrileño de Oncología/Grupo IMO, 28010, Madrid, Spain aut Rivin E. Department of Radiation Oncology, Hospital General Universitario de Elche/ERESA, Elche, Spain aut Sanchez-Reyes A. Radiation Physics, Instituto Madrileño de Oncología/Grupo IMO, Madrid, Spain aut Beltran C. Department of Radiation Oncology, Instituto Madrileño de Oncología/Grupo IMO, 28010, Madrid, Spain aut Bourgier C. Department of Radiation Oncology, Institut de Cancérologie Gustave Roussy, Villejuif, Paris, France aut Calvo F. Department of Oncology, Hospital General Universitario Gregorio Marañon, Madrid, Spain aut Marsiglia H. Department of Radiation Oncology, Instituto Madrileño de Oncología/Grupo IMO, 28010, Madrid, Spain aut Clinical and Translational Oncology Springer Milan 15/6(2013-06-01), 484-491 1699-048X 15:6<484 2013 15 12094 https://doi.org/10.1007/s12094-012-0956-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0956-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Sole C. Department of Radiation Oncology, Instituto Madrileño de Oncología/Grupo IMO, 28010, Madrid, Spain aut NATIONALLICENCE 700 1- Lopez Guerra J. Department of Radiation Oncology, Instituto Madrileño de Oncología/Grupo IMO, 28010, Madrid, Spain aut NATIONALLICENCE 700 1- Matute R. Department of Radiation Oncology, Instituto Madrileño de Oncología/Grupo IMO, 28010, Madrid, Spain aut NATIONALLICENCE 700 1- Jaen J. Department of Radiation Oncology, Instituto Madrileño de Oncología/Grupo IMO, 28010, Madrid, Spain aut NATIONALLICENCE 700 1- Puebla F. Department of Radiation Oncology, Instituto Madrileño de Oncología/Grupo IMO, 28010, Madrid, Spain aut NATIONALLICENCE 700 1- Rivin E. Department of Radiation Oncology, Hospital General Universitario de Elche/ERESA, Elche, Spain aut NATIONALLICENCE 700 1- Sanchez-Reyes A. Radiation Physics, Instituto Madrileño de Oncología/Grupo IMO, Madrid, Spain aut NATIONALLICENCE 700 1- Beltran C. Department of Radiation Oncology, Instituto Madrileño de Oncología/Grupo IMO, 28010, Madrid, Spain aut NATIONALLICENCE 700 1- Bourgier C. Department of Radiation Oncology, Institut de Cancérologie Gustave Roussy, Villejuif, Paris, France aut NATIONALLICENCE 700 1- Calvo F. Department of Oncology, Hospital General Universitario Gregorio Marañon, Madrid, Spain aut NATIONALLICENCE 700 1- Marsiglia H. Department of Radiation Oncology, Instituto Madrileño de Oncología/Grupo IMO, 28010, Madrid, Spain aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/6(2013-06-01), 484-491 1699-048X 15:6<484 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer